FOLFiRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab for Patients with Advanced or Metastatic Adenocarcinoma of The Stomach or Gastroesophageal Junction As Second-Line Therapy - Interim Safety and Efficacy Results from The Phase II Ramiris Study (AIO-STO-0415) of the German Gastric Group at AIO
Zeitschriftentitel:
Oncology Research and Treatment
Jahr:
2020
Band / Volume:
43 Suppl 1
Seitenangaben Beitrag:
58-58
Print-ISSN:
2296-5270
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)